Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Treatment of Age-related Macular

Kijlstra, A, La Heij, EC, and Hendrikse, F, 2005. Immunological factors in the pathogenesis and treatment of age-related macular degeneration. Ocul Immunol Inflamm 13, 3-11. [Pg.345]

Lucentis contains ranibizumab and is available for intravitreal injection. It is a vascular endothelial growth factor inhibitor indicated for the treatment of neovascular (wet) age-related macular degeneration. Unlike verteporfin, which is used in photodynamic treatment of age-related macular degeneration, ranibizumab does not require activation by local irradiation using non-thermal red light. [Pg.154]

A vitronectin (OvjSs integrin) antagonist, 267268, is currently undergoing clinical trials for the treatment of age-related macular degeneration. [Pg.334]

Feher J., Papale A., Mannino G., Gualdi L., and Gabrieli C. B. (2003). Mitotropic compounds for the treatment of age-related macular degeneration - The metabolic approach and a pilot study. Ophthalmologica 217 351-357. [Pg.231]

Hammond, B.R., and Johnson, M.A. Dietary prevention and treatment of age-related macular degeneration, Recent Res. Devel. Nutrition, 5,43-68, 2002. [Pg.104]

Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macmar degeneration with verteporfin. Arch Ophthalmol 1999 117 1329-1345. [Pg.52]

ECT Antiangiogenic Factors for the Treatment of Age-Related Macular Degeneration and Diabetic Retinopathy... [Pg.118]

The efficacy of verteporfin PDT in reducing the risk of vision loss in patients with subfoveal CNV due to AMD was investigated in multicenter, double-masked, placebo-controlled, randomized trials. The Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) study consisted of two identically designed trials conducted in 22 ophthalmology practices in Europe and North America and evaluated PDT for new and recurrent subfoveal CNV with some classic component (8-11). The Verteporfin in Photodynamic Therapy (VIP) study was carried out in 28 practices across Europe and North America and involved patients with only occult CNV or classic CNV with good visual acuity as well as a subset with CNV caused by pathologic myopia (12-14). [Pg.234]

Figure 1 TAP study. Kaplan-Meier estimate of the cumulative proportion of eyes with moderate vision loss (>15 letters) in verteporfin-treated and placebo groups at each three-month study visit. Abbreviation TAP, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy. Source From Ref. 9. Figure 1 TAP study. Kaplan-Meier estimate of the cumulative proportion of eyes with moderate vision loss (>15 letters) in verteporfin-treated and placebo groups at each three-month study visit. Abbreviation TAP, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy. Source From Ref. 9.
Rubin GS, Bressler NM. Effects of verteporfin therapy on contrast on sensitivity results from the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation—TAP report no 4. Retina 2002 22 536-544. [Pg.246]

Another porphyrin-based photosensitizer, benzoporphyrin derivative monoacid A (Verteporphin, Visudyne ), has received approval for treatment of age-related macular degeneration, and a form of pathologic myopia. [Pg.85]

Two essential carotenoids, lutein and zeaxanthin, play an important role in the visual process. For the treatment of age-related macular degeneration (AMD), knowledge of the isomeric composition within the macula is of particular interest [7], Full assignment of isomeric configuration is possible by the registration of two-dimensional proton-proton correlated NMR spectra. Figure 7-7 shows, as an example, the COSY stopped-flow NMR spectrum of all-trans zeaxanthin isolated from ox retina. [Pg.108]

Sharif, N. A. Use of agents that sequester or degrade amyloid-like proteins and drusen in the treatment of age-related macular degeneration. U.S. Pat. Appl. Publ. US 2006121039, 2006 Ghent. Abstr. 2006, 145, 40290. [Pg.92]

Schmucker C, Ehlken C, Hansen LL, Antes G, Agostini HT, Lelgemann M. Intravi-treal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration a systematic review. Curr Opin Ophthalmol 2010 21 218-26. [Pg.766]

Li F, et al. Controlled release of be vacizumab through nanospheres for extended treatment of age-related macular degeneration. Open Ophthalmol J 2012 6 54-8. [Pg.520]

Over the past decade or so, PDT has been developed and approved for treatment of age-related macular degeneration (AMD-wet form), as mentioned above in the context of 2-photon PDT. Since the idea is to close down the choroidal neovasculature and so prevent further progression of the disease, the light is applied while the photosensitizer (benzoporphyrin derivative, Visudyne , QLT, Canada) is still in the blood vessels. [Pg.263]

See other pages where Treatment of Age-related Macular is mentioned: [Pg.1256]    [Pg.163]    [Pg.509]    [Pg.198]    [Pg.121]    [Pg.461]    [Pg.408]    [Pg.260]    [Pg.408]    [Pg.494]    [Pg.403]    [Pg.1256]    [Pg.304]    [Pg.637]    [Pg.147]    [Pg.391]    [Pg.204]    [Pg.464]    [Pg.195]    [Pg.1217]    [Pg.217]    [Pg.225]    [Pg.180]    [Pg.391]    [Pg.1356]    [Pg.80]    [Pg.113]   


SEARCH



Age-related macular

Macular

© 2024 chempedia.info